^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | temozolomide (DNA synthesis inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy
Published date:
06/01/2022
Excerpt:
Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation. Five achieved confirmed partial response, with an objective response rate of 17.2%. The disease control rate was 82.8%....Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma...
DOI:
10.1097/CMR.0000000000000809
Trial ID:
